Forecast

The analysts' average price target is €11.51 (+70.01%). The median is €3.45 (-49.04%).

Buy	0
Hold	5
Sell	0

News Go to news feed

Athira Pharma to be renamed LeonaBio, shifts focus to cancer therapy with Lasofoxifen

Athira Pharma is rebranding as LeonaBio and will trade under the ticker LONA from January 12, 2026. The move follows acquisition of the global (excluding Asia and parts of the Middle East) rights to lasofoxifen, a phase‑3 candidate for metastatic breast cancer; the ELAINE‑3 trial is over 50% recruited and results are expected mid‑2027. In a private placement the company secured immediate financing of $90 million with a potential additional $146 million through option exercise; the funds are intended to support operations through 2028. The ALS candidate ATH‑1105 remains in the pipeline, with a phase‑2 study planned to start in early 2026. » More on de.investing.com
Athira Pharma takes over phase‑3 breast cancer drug Lasofoxifen and announces financing round

Athira Pharma has acquired worldwide development and commercialization rights for Lasofoxifen from Sermonix — a SERM in phase 3 for the treatment of metastatic breast cancer with ESR1 mutations. The ongoing ELAINE‑3 study is more than 50% recruited, with study data expected mid‑2027; earlier ELAINE‑2 data showed a median progression‑free survival of 13 months. To support the program, Athira announced a private placement of $90 million with warrants (potentially up to $146 million); additionally, up to $100 million in milestone payments and royalties are envisaged. » More on de.investing.com
Athira Pharma reports quarterly EPS of -$1.68 (prior year -$7.50)

On Nov. 6, 2025, Athira Pharma released results for the most recent quarter and reported earnings per share (EPS) of -$1.68. In the same quarter a year earlier, EPS was -$7.50. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, ATHIRA PHARMA INC. -,0001 has already paid €0.0842 in dividends. The last payout was in June 2022.

Financials

In the last quarter, ATHIRA PHARMA INC. -,0001 had revenue of €0 and net profit of -€16.65M

(EUR)	Jun 2026	YoY
Revenue	0	-
Gross profit	0	100.00%
Net profit	-16.65M	181.79%
EBITDA	-17.04M	196.93%

Fundamentals

Metric	Value
Market capitalization	€22.98M
Number of shares	3.94M
52-week high/low	€7.22 - €1.89
Dividends	No
Beta	2.80
P/E ratio	-0.24
PEG ratio	0.00
P/B ratio	0.99
P/S ratio	0.00

Company profile

Athira Pharma, Inc. ist ein biopharmazeutisches Unternehmen im späten klinischen Stadium, das sich auf die Entwicklung kleiner Moleküle zur Wiederherstellung der neuronalen Gesundheit und zur Verlangsamung des neurodegenerativen Abbaus konzentriert. Der führende Produktkandidat des Unternehmens ist ATH-1017, ein die Blut-Hirn-Schranke durchdringender, niedermolekularer HGF/MET-positiver Modulator, der sich in den klinischen Studien der Phasen LIFT-AD (Phase 3) und ACT-AD (Phase 2) zur Behandlung der Alzheimer-Krankheit sowie in klinischen Studien der Phase 2 zur Behandlung der Parkinson-Krankheit befindet. Das Unternehmen entwickelt auch Produktkandidaten, die sich im präklinischen Stadium befinden, darunter ATH-1019 für Indikationen des peripheren Nervensystems und ATH-1020 für neuropsychiatrische Erkrankungen. Athira Pharma, Inc. war früher als M3 Biotechnology, Inc. bekannt und änderte im April 2019 seinen Namen in Athira Pharma, Inc. Das Unternehmen wurde im Jahr 2011 gegründet und hat seinen Hauptsitz in Bothell, Washington.

Name	ATHIRA PHARMA INC. -,0001
CEO	Mark J. Litton
Headquarters	Bothell, wa USA
Website	athira.com
Sector	Consumer Staples
Industry	Food Products
IPO	09/18/2020
Employees	26